Scarica l'app Stockscreener
6.60
1.69%
0.11
Dopo l'orario di chiusura:
6.89
0.29
+4.39%
Precedente Chiudi:
$6.49
Aprire:
$6.38
Volume 24 ore:
1.21M
Relative Volume:
0.92
Capitalizzazione di mercato:
$572.86M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-3.0415
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
+10.74%
1M Prestazione:
+3.94%
6M Prestazione:
-20.29%
1 anno Prestazione:
-65.34%
Intervallo 1D:
$6.35
$6.66
Intervallo di 1 settimana:
$5.45
$6.735
Portata 52W:
$5.41
$21.57
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
6.60 | 563.31M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Price Consolidation Hints at Upcoming Move in Kura Oncology Inc.2025 Fundamental Recap & Weekly Setup with ROI Potential - sundaytimes.kr
Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold? - AInvest
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Kura Oncology Inc. stock attracts strong analyst attentionDouble in 10 Days Stock Ideas - newsyoung.net
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Nigeria
JMP Securities Maintains Market Outperform on Kura Oncology with New PT of $24 - AInvest
Kura Oncology stock price target lowered to $24 at Citizens JMP - Investing.com Canada
Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Is Kura Oncology Inc. stock entering bullish territoryDividend Strategy Summary With 10-Year Outlook - Newser
What makes Kura Oncology Inc. stock price move sharplyFree Daily Chart Pattern Stock Forecast - Newser
How hedge fund analytics apply to Kura Oncology Inc. stockROI Focused Setup Screener With Exit Markers - Newser
Order flow analysis tools used on Kura Oncology Inc.Equity Performance Forecast Based on AI Models - Newser
Chart based analysis of Kura Oncology Inc. trendsFree Short Term Buy Zone Stock Alerts - Newser
Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru
How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser
Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest
Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks
Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast - Investing.com Nigeria
Kura Oncology: Q2 Earnings Snapshot - Connecticut Post
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses By GuruFocus - Investing.com Canada
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
Kura Oncology Advances Cancer Drug Pipeline with FDA Review - TipRanks
Published on: 2025-08-07 23:14:29 - Newser
Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
Kura Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology Reports Second Quarter 2025 Financial Results | KU - GuruFocus
Kura Oncology Inc earnings missed by $0.34, revenue fell short of estimates - Investing.com South Africa
Q2 2025 Kura Oncology Inc Earnings Call Transcript - GuruFocus
Kura Oncology Reports Second Quarter 2025 Financial Results - Yahoo Finance
Dimensional US Core Equity 2 ETF (DFAC) Implied Analyst Target Price: $41.37, With 12.92% Upside Expected. - AInvest
Kura Oncology Grants Inducement Stock Options to New Employees Under Nasdaq Listing Rule - AInvest
Kura Oncology KURA Q2 2025 Earnings Preview Upside Potential on Robust Revenue Forecast - AInvest
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology grants stock options to new employees under inducement plan. - AInvest
Cancer Drug Developer Kura Oncology Makes Major Hiring Push: 35 New Scientists Join Precision Medicine Team - Stock Titan
How strong is Kura Oncology Inc. company’s balance sheetUnlock powerful investment tools for free - Jammu Links News
What are the technical indicators suggesting about Kura Oncology Inc.Unlock powerful trading signals and alerts - Jammu Links News
What markets is Kura Oncology Inc. expanding into Is GURE stock a good long term investment optionTremendous gains - Jammu Links News
What institutional investors are buying Kura Oncology Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
What drives Kura Oncology Inc. stock priceUnmatched profit potential - Jammu Links News
What are analysts’ price targets for Kura Oncology Inc. in the next 12 monthsDiscover stocks with explosive upside potential - Jammu Links News
Why is Kura Oncology Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Using flow based indicators on Kura Oncology Inc.Asset Allocation Summary With Future Outlook - Newser
What are the latest earnings results for Kura Oncology Inc.Fast-track wealth growth - Jammu Links News
Kura Oncology targets 2028 MRD-negative CR results for frontline AML trials - MSN
Is Kura Oncology Inc. the Top Chart Pick This WeekOptimized Return Investment Picks - beatles.ru
How does Kura Oncology Inc. generate profit in a changing economyEntry Signal Report For Beginners - jammulinksnews.com
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):